Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fierce Health vs MyFastRx

Fierce Health
Graded #410

Lower grade

vs+10.999999999999993
MyFastRx
Graded #161

Higher grade

The verdict

MyFastRx takes it — 67.6/100 to 56.6/100.

MyFastRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyFastRx is a cash-pay compounded-GLP-1 platform built around fast approval and discounted multi-month bundles.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMyFastRx +43
33
76
Dose & formulationFierce Health +5
77
72
Clinical oversightMyFastRx +4
62
66
Labs & monitoringEven
52
52
FulfillmentMyFastRx +8
75
83
Contract termsFierce Health +6
47
41
Fierce Health · left barMyFastRx · right bar

The numbers

MetricFierce HealthMyFastRx
WeighScore56.6/10067.6/100
GradeCC
Scorecard rank#410#161
Semaglutide$297/mo (3-month plan, compounded)$169/mo
Tirzepatide$497/mo (3-month plan, compounded)$249/mo
Coverage30 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Fierce Health

Graded #410 · C

Strengths

  • 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer on every product page
  • Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
  • Microdose tier at $197/mo is one of the lower entry points we've seen

Where it loses points

  • No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
  • Operating LLC name not disclosed anywhere on the site
  • Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
  • Clinical provider network not named
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
MyFastRx

Graded #161 · C

Strengths

  • Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
  • LegitScript certified
  • All doses priced the same — no cost escalation as you titrate up
  • First-month promo discount lowers the trial barrier

Where it loses points

  • States served not disclosed — only 'multiple states' / 'licensed U.S. providers'
  • Corporate address and medical director not published
  • Pharmacy partner not named — only 'state-licensed pharmacies'
  • Cash-pay only — no insurance billing
  • Bundle savings require a large upfront commitment (12 months billed at once)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard